Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report
Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor of the liver and gallbladder, which is usually diagnosed at an advanced stage and the opportunity for surgery is lost. Therefore, conversion therapy is important to convert the iCCA into a resectable state. In recent years, the conve...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1476593/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527858550276096 |
|---|---|
| author | Shuangying Zhao Xiaodong Zhang Jialiang Luo Huanjun Yan Jianlei Zhang Rongfeng Lin Kelei Zhu |
| author_facet | Shuangying Zhao Xiaodong Zhang Jialiang Luo Huanjun Yan Jianlei Zhang Rongfeng Lin Kelei Zhu |
| author_sort | Shuangying Zhao |
| collection | DOAJ |
| description | Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor of the liver and gallbladder, which is usually diagnosed at an advanced stage and the opportunity for surgery is lost. Therefore, conversion therapy is important to convert the iCCA into a resectable state. In recent years, the conversion protocol of immuno-chemotherapy has been applied for advanced liver cancer. However, little has been reported about iCCA conversion therapy. The aim of this report is to present the results of conversion therapy with Gemcitabine plus S-1 (GS) combined with PD-1 inhibitors (Zimberelimab) in a 74-year-old female IIIB iCCA patient. After 6 cycles of conversion therapy, enhanced CT showed that the patient’s tumor had shrunk to nearly half its original size, making radical resection possible. Postoperative pathology showed a complete pathological response. This provides a new way to convert advanced iCCA into resectable state. |
| format | Article |
| id | doaj-art-d1c7ac1db28c4def83440518087b8c39 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-d1c7ac1db28c4def83440518087b8c392025-01-15T06:10:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14765931476593Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case reportShuangying Zhao0Xiaodong Zhang1Jialiang Luo2Huanjun Yan3Jianlei Zhang4Rongfeng Lin5Kelei Zhu6Department of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, ChinaDepartment of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, ChinaHealth Science Center, Ningbo University, Ningbo, ChinaDepartment of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, ChinaDepartment of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, ChinaDepartment of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, ChinaDepartment of Hepatopancreatobiliary Surgery, The Affiliated People’s Hospital of Ningbo University, Ningbo, ChinaIntrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor of the liver and gallbladder, which is usually diagnosed at an advanced stage and the opportunity for surgery is lost. Therefore, conversion therapy is important to convert the iCCA into a resectable state. In recent years, the conversion protocol of immuno-chemotherapy has been applied for advanced liver cancer. However, little has been reported about iCCA conversion therapy. The aim of this report is to present the results of conversion therapy with Gemcitabine plus S-1 (GS) combined with PD-1 inhibitors (Zimberelimab) in a 74-year-old female IIIB iCCA patient. After 6 cycles of conversion therapy, enhanced CT showed that the patient’s tumor had shrunk to nearly half its original size, making radical resection possible. Postoperative pathology showed a complete pathological response. This provides a new way to convert advanced iCCA into resectable state.https://www.frontiersin.org/articles/10.3389/fonc.2024.1476593/fullintrahepatic cholangiocarcinomaconversion therapycase reportimmunotherapy combined therapyPD-1 |
| spellingShingle | Shuangying Zhao Xiaodong Zhang Jialiang Luo Huanjun Yan Jianlei Zhang Rongfeng Lin Kelei Zhu Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report Frontiers in Oncology intrahepatic cholangiocarcinoma conversion therapy case report immunotherapy combined therapy PD-1 |
| title | Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report |
| title_full | Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report |
| title_fullStr | Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report |
| title_full_unstemmed | Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report |
| title_short | Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report |
| title_sort | conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus s 1 combined with pd 1 inhibitors a case report |
| topic | intrahepatic cholangiocarcinoma conversion therapy case report immunotherapy combined therapy PD-1 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1476593/full |
| work_keys_str_mv | AT shuangyingzhao conversiontherapyforunresectableintrahepaticcholangiocarcinomausinggemcitabinepluss1combinedwithpd1inhibitorsacasereport AT xiaodongzhang conversiontherapyforunresectableintrahepaticcholangiocarcinomausinggemcitabinepluss1combinedwithpd1inhibitorsacasereport AT jialiangluo conversiontherapyforunresectableintrahepaticcholangiocarcinomausinggemcitabinepluss1combinedwithpd1inhibitorsacasereport AT huanjunyan conversiontherapyforunresectableintrahepaticcholangiocarcinomausinggemcitabinepluss1combinedwithpd1inhibitorsacasereport AT jianleizhang conversiontherapyforunresectableintrahepaticcholangiocarcinomausinggemcitabinepluss1combinedwithpd1inhibitorsacasereport AT rongfenglin conversiontherapyforunresectableintrahepaticcholangiocarcinomausinggemcitabinepluss1combinedwithpd1inhibitorsacasereport AT keleizhu conversiontherapyforunresectableintrahepaticcholangiocarcinomausinggemcitabinepluss1combinedwithpd1inhibitorsacasereport |